Overview

* Apyx Medical ( APYX ) Q2 revenue falls 6.4% yr/yr, missing analyst expectations, per LSEG data

* Net loss narrows to $3.8 mln, adjusted EBITDA loss improves to $2.0 mln

* Co raises FY2025 revenue guidance to $50-52 mln on strong AYON pre-sales

Outlook

* Company raises FY2025 revenue guidance to $50.0 mln-$52.0 mln

* Apyx expects Advanced Energy revenue of $42.0 mln-$44.0 mln for FY2025

* Company projects OEM revenue at approximately $8.0 mln for FY2025

* Apyx anticipates operating expenses below $40.0 mln for FY2025

Result Drivers

* AYON LAUNCH - Successful launch of AYON Body Contouring System exceeded customer demand expectations, per CEO Charlie Goodwin

* RENUVION IN CHINA - Strong clinical interest and initial procedures completed following Renuvion's commercial sales launch in China

* OPERATING EXPENSES - Decrease in operating expenses contributed to a narrower net loss in Q2 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Miss $11.37 $11.70

mln mln (3

Analysts

)

Q2 EPS -$0.09

Q2 Net -$3.74

Income mln

Q2 Miss -$1.96 -$1.68

Adjusted mln mln (2

EBITDA Analysts

)

Q2 Gross 62.3%

Margin

Q2 -$2.57

Income mln

From

Operatio

ns

Q2 -$3.69

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Apyx Medical Corp ( APYX ) is $4.00, about 49% above its August 6 closing price of $2.04

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)